April 4, 2005
Drug to be tested for breast-cancer preventionTopics: Clinical Pharmacology
In post-menopausal women, estrogen is no longer produced by the ovaries, but is converted from another hormone, called androgen. Aromatase inhibitors keep androgen from being converted to estrogen. That means less estrogen in the bloodstream, and less estrogen reaching estrogen receptors to trigger trouble.
According to an article in the March 31, 2005 GlobeandMail.com, breast-cancer researcher Dr. Paul Goss is seeking to answer the question of whether drugs called aromatase inhibitors have a role to play in disease prevention in women after they go through menopause - the time of life when three-quarters of breast cancers are diagnosed.
Researchers in Canada and the United States are embarking on a clinical trial to see if a drug that is highly effective in treating breast cancer could be used to prevent it.
(...) Currently, there is little that doctors can offer women who are at high risk of developing breast cancer, apart from the always sage advice to eat a healthy diet and exercise.
(...) Half will receive exemestane and the other half will receive a placebo. Neither the women nor their doctors will know which participants are getting the drug. Treatment will continue for five years, and the women will be followed well after that, Dr. Goss said, to compare breast-cancer rates among those who took the drug and those who did not.
cross posted at Hyscience
Posted by Richard at April 4, 2005 10:56 PM
Articles Related to Clinical Pharmacology: